Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227144 · ClinicalTrials.gov registry record · Phase 1
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by ORIC Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT05227144 is a Phase 1 study that has completed, run by ORIC Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT05227144, a Phase 1 study, has completed, sponsored by ORIC Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
Interventions
- DRUG ORIC-533
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-01-06 |
| Est. Completion | 2025-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227144
The ClinicalTrials.gov registry entry for NCT05227144 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ORIC Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ORIC-533 is the first listed.
NCT05227144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05227144 about?
NCT05227144 is a clinical study titled "Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma". The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
What is the current status of trial NCT05227144?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2022-01-06. Estimated completion is 2025-03-03.
What interventions are being tested in trial NCT05227144?
The interventions under investigation include: ORIC-533 (DRUG).
Who is sponsoring clinical trial NCT05227144?
This trial is sponsored by ORIC Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.